Invention Grant
- Patent Title: SPNS2 neutralizing antibody
-
Application No.: US17045398Application Date: 2019-04-05
-
Publication No.: US11667707B2Publication Date: 2023-06-06
- Inventor: Kenta Hibiya , Yusuke Kanamaru , Hirotsugu Kato
- Applicant: Teijin Pharma Limited
- Applicant Address: JP Tokyo
- Assignee: Teijin Pharma Limited
- Current Assignee: Teijin Pharma Limited
- Current Assignee Address: JP Tokyo
- Agency: Sughrue Mion, PLLC
- Priority: JP 2018073940 2018.04.06
- International Application: PCT/JP2019/015208 2019.04.05
- International Announcement: WO2019/194314A 2019.10.10
- Date entered country: 2020-10-05
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61P35/00 ; A61P37/06 ; C07K16/18 ; C12N15/63 ; A61K45/06 ; A61K39/00
Abstract:
The purpose of the present invention is to provide an antibody that can be expected to have a therapeutic effect in autoimmune diseases and anticancer treatment by inhibiting S1P transport by SPNS2 to thereby inhibit lymphocyte migration. The present invention is an SPNS2 neutralizing antibody or a fragment thereof, or a derivative thereof, that specifically binds to vertebrate SPNS2 and has lymphocyte migration inhibitory activity through SW transport inhibition.
Public/Granted literature
- US20210147523A1 SPNS2 NEUTRALIZING ANTIBODY Public/Granted day:2021-05-20
Information query
